During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount Sinai, New York, US. Brody discussed the key highlights in lymphoma and chronic lymphocytic leukemia (CLL) from the meeting.

Brody highlights several presentations on approved and novel immunotherapies for patients with lymphoma and CLL. He discusses the significant progress made in the treatment of B-cell non-Hodgkin lymphoma (NHL). He also discusses the historically poor outcomes in patients with T-cell lymphoma and highlights some of the novel therapies presented at ASH for this patient population.

Hosted on Acast. See acast.com/privacy for more information.

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Alexey Danilov, City of Hope Comprehensive Cancer Center, Duarte, US. We asked, What are the latest updates from the phase I NX-5948-301 trial of bexobrutideg in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)?

This educational resource is independently supported by Nurix. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

The Lymphoma Hub was pleased to speak to Susan O’Brien, Chao Family Comprehensive Cancer Center, University of California, Irvine, US. We asked, What do the clinical data tell us about fixed-duration ibrutinib + venetoclax for patients with chronic lymphocytic leukemia (CLL)?

This educational resource is independently supported by Johnson & Johnson. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.